The new Hotspur devices are focused on solving some of the key challenges resulting from medical procedures for restoring bloodflow where physicians use multiple catheters to clear the blood vessels which is time-consuming and expensive. Hotspur’s products enable insertion of only one catheter for the entire procedure.
Hotspur said that the VisioValve injection system technology allows a physician to complete an entire angioplasty or clot treatment and perform an injection of specified fluids without having to remove the guidewire or exchange devices.
The IQCath Balloon Dilatation Catheter is a three-in-one device that allows a physician to conduct PTA, fluid injection and perform thrombectomy while maintaining guidewire position. It is intended to be used within synthetic arteriovenous dialysis fistulae to remove embolic material (thrombus/debris) and dilate stenosis for treatment of obstructive lesions.
The GPSCath Balloon Dilatation Catheter follows the lead of the IQCath Balloon Dilatation Catheter and is a two-in-one device that allows the physician to conduct angioplasty and fluid injection while maintaining guidewire position. It is intended to be used for angioplasty of the femoral, iliac and renal arteries, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.
The Keeper Embolectomy Catheter is another two-in-one device which integrates an embolectomy balloon with the ability to inject physician-specified fluids while maintaining guidewire position. It is intended to be used within vessels in the arterial system and synthetic arteriovenous dialysis fistulae for the removal of fresh, soft emboli and thrombi.
Hotspur said that all the three products are expected to be commercially available by the end of the current year. The IQCath and GPSCath Catheters are used for dialysis applications and also PAD procedures.
Gwen Watanabe, president and CEO of Hotspur Technologies, said: “We are excited about the benefits our technologies will bring in peripheral and dialysis access interventions. Making peripheral vascular procedures faster and more efficient so that doctors can perform more cases and patients can get out of the interventional suite or the dialysis access centers more quickly is the focus of our innovations.”
